Skip to main content
Figure 2 | Radiation Oncology

Figure 2

From: Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment

Figure 2

Pontine necrosis after SBRT. This patient was a 48-year-old male with type I NPC (a). He was treated with cisplatin-based concurrent chemoradiation via EBRT up to 59.4 Gy followed by CK-RS at 25 Gy in 5 fractions (b) and achieved CR in the response evaluation (c). Pontine necrosis developed 25.9 months after SBRT (d). He experienced various neurologic symptoms, including dizziness, gait disturbance, hoarseness, limb weakness, dysarthria and other cranial nerve signs and was still under rehabilitation and supportive care for debilitating symptoms at the time of analysis.

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us